Get the Stockscreener App
126.86
1.25%
-1.61
After Hours:
126.66
-0.20
-0.16%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $126.86, with a volume of 5.76M.
It is down -1.25% in the last 24 hours and down -2.86% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$128.47
Open:
$128.41
24h Volume:
5.76M
Relative Volume:
0.93
Market Cap:
$220.59B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.91
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
+4.63%
1M Performance:
-2.86%
6M Performance:
-5.34%
1Y Performance:
+12.64%
1-Day Range:
$126.30
$128.60
1-Week Range:
$120.70
$129.64
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.86 | 223.39B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.95 | 136.67B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.69 | 135.88B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.72 | 126.37B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.32 | 48.39B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Seeks Federal Protection From Similac NEC Lawsuits - AboutLawsuits.com
TruWealth Advisors LLC Sells 109,352 Shares of Abbott Laboratories $ABT - MarketBeat
Insight Wealth Strategies LLC Invests $4.91 Million in Abbott Laboratories $ABT - MarketBeat
These Surging Dividend Stocks Are the Next AI Winners and Wall Street Hates Them - Investing.com
Capital Asset Advisory Services LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Home Diagnostics Market Is Going to Boom |• Abbott • Roche Diagnostics - openPR.com
Kidney Function Tests Market Is Going to Boom |• Abbott • Siemens - openPR.com
Why the Market Dipped But Abbott (ABT) Gained Today - Yahoo Finance Singapore
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Abbott Gains From Lingo CGM's Expansion on Android Platform - TradingView — Track All Markets
Rep. Julie Johnson Sells Abbott Laboratories (NYSE:ABT) Stock - MarketBeat
Texas Permanent School Fund Corp Sells 65,976 Shares of Abbott Laboratories $ABT - MarketBeat
Stance Capital LLC Makes New $1.30 Million Investment in Abbott Laboratories $ABT - MarketBeat
Prostate Cancer Diagnostics Market Is Going to Boom |• Abbott • Siemens - openPR.com
Corient Private Wealth LLC Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Caldwell Trust Co Takes Position in Abbott Laboratories $ABT - MarketBeat
17,830 Shares in Abbott Laboratories $ABT Bought by B. Riley Wealth Advisors Inc. - MarketBeat
Abbott Laboratories Strengthens Shareholder Returns Amid Strategic Acquisition - AD HOC NEWS
Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025 - ts2.tech
Westwood Holdings Group Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Provident Investment Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Public Sector Pension Investment Board - MarketBeat
Key facts: Abbott Laboratories appoints Nita Ahuja to Board; VP reports share gift - TradingView — Track All Markets
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
Elevatus Welath Management Boosts Position in Abbott Laboratories $ABT - MarketBeat
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet? - Yahoo Finance
Curi Capital LLC Acquires 53,244 Shares of Abbott Laboratories $ABT - MarketBeat
Benjamin Edwards Inc. Has $45.44 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
Banque Transatlantique SA Trims Stake in Abbott Laboratories $ABT - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Sells 70,936 Shares of Abbott Laboratories $ABT - MarketBeat
Ameriprise Financial Inc. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Boosted by Adage Capital Partners GP L.L.C. - MarketBeat
Abbott Laboratories (ABT) Expands Board of Directors with New Ap - GuruFocus
Abbott Laboratories Expands Board with New Appointment - TipRanks
Abbott Laboratories (ABT) Stock: Dividend Boost and Major Acquisition Drive 2026 Outlook - CoinCentral
Abbott Laboratories (ABT) Boosts Quarterly Dividend by 6.8% - GuruFocus
Abbott Laboratories Declares 408th Consecutive Quarterly Cash Common Dividend, Payable on February 13, 2026 - marketscreener.com
Abbott (ABT) Raises Quarterly Dividend by 6.8% - GuruFocus
Abbott Raises Quarterly Dividend to $0.63 a Share, Payable Feb. 13 to Holders of Record as of Jan. 15 - marketscreener.com
Abbott increases quarterly dividend by 6.8% for 54th consecutive year - Investing.com
Abbott increases quarterly dividend for 54th consecutive year - PR Newswire
Abbott Laboratories (ABT) Receives a Buy from Citi - The Globe and Mail
Abbott Laboratories price tries to recoup some lossesForecast today12-12-2025 - Economies.com
Quantinno Capital Management LP Purchases 113,751 Shares of Abbott Laboratories $ABT - MarketBeat
Assessing Abbott (ABT) Valuation After New Lingo CGM Expansion and Protein-Glucose Data Release - simplywall.st
Peapack Gladstone Financial Corp Buys 23,212 Shares of Abbott Laboratories $ABT - MarketBeat
Ieq Capital LLC Acquires 28,181 Shares of Abbott Laboratories $ABT - MarketBeat
Laird Norton Wetherby Trust Company LLC Has $7.36 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Life Experiences Shape Our Work - Abbott
Technology that connects you to what matters most: Your health - Abbott
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):